DarioHealth Corp. announced its fourth-quarter and full-year 2024 financial results on March 10, 2025, highlighting substantial improvements. Q4 2024 revenue reached $7.6 million, a 110% increase year-over-year, contributing to a full-year 2024 revenue of $27.0 million, up 32.9% from 2023. The Business-to-Business-to-Consumer (B2B2C) recurring revenue surged 398% year-over-year in Q4 to $5.6 million, and 300% for the full year to $20.0 million.
Gross profit for Q4 2024 was $4.2 million, an increase of 3,080% year-over-year, with gross profit as a percentage of revenues rising to 55.3%. For the full year, gross profit increased by 122% to $13.3 million, and the pro-forma gross profit margin reached 67.7%. The company also reported a 35% reduction in operating loss from Q1 2024 to Q4 2024, with Q4 operating loss at $11.7 million.
DarioHealth secured 36 new clients in 2024, expanding its total client base to 83 organizations, and maintained a client renewal rate above 90%. The company anticipates an additional 20% reduction in operating expenses by Q4 2025 and remains on track to achieve an operational cash flow breakeven run rate by the end of 2025. Strategic expansions include enhanced GLP-1 capabilities with MediOrbis and integration of Dario Mind with Rula's network of over 15,000 providers.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.